Human Investing LLC Sells 795 Shares of Abbott Laboratories (NYSE:ABT)

Human Investing LLC lessened its position in shares of Abbott Laboratories (NYSE:ABTFree Report) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,020 shares of the healthcare product maker’s stock after selling 795 shares during the quarter. Human Investing LLC’s holdings in Abbott Laboratories were worth $553,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of ABT. WealthPlan Investment Management LLC raised its position in shares of Abbott Laboratories by 84.1% during the third quarter. WealthPlan Investment Management LLC now owns 82,564 shares of the healthcare product maker’s stock worth $7,996,000 after acquiring an additional 37,715 shares during the last quarter. Victory Capital Management Inc. grew its position in Abbott Laboratories by 1.3% during the third quarter. Victory Capital Management Inc. now owns 624,689 shares of the healthcare product maker’s stock worth $60,501,000 after buying an additional 7,999 shares in the last quarter. Wealthspire Advisors LLC boosted its holdings in shares of Abbott Laboratories by 10.3% in the 3rd quarter. Wealthspire Advisors LLC now owns 40,698 shares of the healthcare product maker’s stock valued at $3,942,000 after purchasing an additional 3,800 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Abbott Laboratories by 4.5% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,630,903 shares of the healthcare product maker’s stock valued at $545,353,000 after purchasing an additional 242,244 shares in the last quarter. Finally, Cornerstone Wealth Management LLC boosted its holdings in shares of Abbott Laboratories by 10.2% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 12,220 shares of the healthcare product maker’s stock valued at $1,184,000 after acquiring an additional 1,132 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $14,895,094.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of Abbott Laboratories stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at approximately $14,895,094.50. The disclosure for this sale can be found here. Insiders sold a total of 34,384 shares of company stock worth $3,653,916 in the last three months. Company insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent research reports. Raymond James reissued a “buy” rating and set a $124.00 price objective on shares of Abbott Laboratories in a report on Wednesday, April 24th. Royal Bank of Canada cut their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, April 18th. Evercore ISI raised their target price on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Barclays lowered their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, April 22nd. Finally, Citigroup lowered their target price on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a research report on Wednesday, May 22nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $120.60.

Get Our Latest Stock Analysis on ABT

Abbott Laboratories Trading Down 0.3 %

Shares of ABT stock traded down $0.28 during mid-day trading on Monday, hitting $103.95. The company’s stock had a trading volume of 4,455,800 shares, compared to its average volume of 5,639,877. The company’s fifty day simple moving average is $108.08 and its 200-day simple moving average is $109.74. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.11 and a current ratio of 1.60. The company has a market cap of $180.83 billion, a PE ratio of 32.38, a P/E/G ratio of 2.50 and a beta of 0.76.

Abbott Laboratories (NYSE:ABTGet Free Report) last issued its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The firm’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period last year, the business posted $1.03 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

About Abbott Laboratories

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.